References
1. Halliday, H.L., The fascinating story of surfactant. Journal of Paediatrics and Child Health, 2017. 53 (4): p. 327-332.
2. Obladen, M., History of surfactant up to 1980. Biol Neonate, 2005. 87 (4): p. 308-16.
3. Gruenwald, P., Surface tension as a factor in the resistance of neonatal lungs to aeration. Am J Obstet Gynecol, 1947. 53 (6): p. 996-1007.
4. AVERY, M.E. and J. MEAD, Surface Properties in Relation to Atelectasis and Hyaline Membrane Disease. A.M.A. Journal of Diseases of Children, 1959. 97 (5_PART_I): p. 517-523.
5. Halliday, H.L., Surfactants: past, present and future. Journal of Perinatology, 2008. 28 (1): p. S47-S56.
6. Pattle, R.E., Properties, function and origin of the alveolar lining layer. Nature, 1955. 175 (4469): p. 1125-6.
7. Weibel, E.R., W. Limacher, and H. Bachofen, Electron microscopy of rapidly frozen lungs: evaluation on the basis of standard criteria.Journal of Applied Physiology, 1982. 53 (2): p. 516-527.
8. Perez-Gil, J. and T.E. Weaver, Pulmonary surfactant pathophysiology: current models and open questions. Physiology (Bethesda), 2010. 25 (3): p. 132-41.
9. Albert, R.K., The Role of Ventilation-induced Surfactant Dysfunction and Atelectasis in Causing Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2012. 185 (7): p. 702-708.
10. Wright, J.R., Immunoregulatory functions of surfactant proteins. Nature Reviews Immunology, 2005. 5 (1): p. 58-68.
11. Wright, J.R., Immunomodulatory functions of surfactant.Physiol Rev, 1997. 77 (4): p. 931-62.
12. Hime, N.J., et al., Childhood interstitial lung disease: A systematic review. Pediatric Pulmonology, 2015. 50 (12): p. 1383-1392.
13. Gower, W.A. and L.M. Nogee, Surfactant dysfunction.Paediatric respiratory reviews, 2011. 12 (4): p. 223-229.
14. Ridsdale, R. and M. Post, Surfactant lipid synthesis and lamellar body formation in glycogen-laden type II cells. American Journal of Physiology-Lung Cellular and Molecular Physiology, 2004.287 (4): p. L743-L751.
15. Weaver, T.E., C.-L. Na, and M. Stahlman, Biogenesis of lamellar bodies, lysosome-related organelles involved in storage and secretion of pulmonary surfactant. Seminars in Cell & Developmental Biology, 2002. 13 (4): p. 263-270.
16. Matsuzaki, Y., et al., STAT3 Regulates ABCA3 Expression and Influences Lamellar Body Formation in Alveolar Type II Cells. American Journal of Respiratory Cell and Molecular Biology, 2008. 38 (5): p. 551-558.
17. Oosterlaken-Dijksterhuis, M.A., et al., Characterization of lipid insertion into monomolecular layers mediated by lung surfactant proteins SP-B and SP-C. Biochemistry, 1991. 30 (45): p. 10965-10971.
18. Hamvas, A., Inherited Surfactant Protein-B Deficiency and Surfactant Protein-C Associated Disease: Clinical Features and Evaluation. Seminars in Perinatology, 2006. 30 (6): p. 316-326.
19. King, R.J. and M.C. MacBeth, Interaction of the lipid and protein components of pulmonary surfactant Role of phosphatidylglycerol and calcium. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1981.647 (2): p. 159-168.
20. Ingenito, E.P., et al., Biophysical characterization and modeling of lung surfactant components. Journal of Applied Physiology, 1999. 86 (5): p. 1702-1714.
21. Numata, M., et al., Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus–induced inflammation and infection. Proceedings of the National Academy of Sciences, 2010.107 (1): p. 320-325.
22. Kandasamy, P., et al., Pulmonary surfactant phosphatidylglycerol inhibits Mycoplasma pneumoniae-stimulated eicosanoid production from human and mouse macrophages. Journal of Biological Chemistry, 2011. 286 (10): p. 7841-7853.
23. Han, S. and R.K. Mallampalli, The role of surfactant in lung disease and host defense against pulmonary infections. Annals of the American Thoracic Society, 2015. 12 (5): p. 765-774.
24. Veldhuizen, E.J.A. and H.P. Haagsman, Role of pulmonary surfactant components in surface film formation and dynamics.Biochimica et Biophysica Acta (BBA) - Biomembranes, 2000.1467 (2): p. 255-270.
25. Whitsett, J.A. and T.E. Weaver, Chapter 2 - Hereditary Disorders of Alveolar Homeostasis in the Newborn , in The Newborn Lung , R.A. Polin and E. Bancalari, Editors. 2008, W.B. Saunders: Philadelphia. p. 42-49.
26. Stahlman, M.T., et al., Expression of ABCA3 in Developing Lung and Other Tissues. Journal of Histochemistry & Cytochemistry, 2007.55 (1): p. 71-83.
27. Possmayer, F., A Proposed Nomenclature for Pulmonary Surfactant-associated Proteins. American Review of Respiratory Disease, 1988. 138 (4): p. 990-998.
28. Sano, H. and Y. Kuroki, The lung collectins, SP-A and SP-D, modulate pulmonary innate immunity. Molecular immunology, 2005.42 (3): p. 279-287.
29. Carreto-Binaghi, L.E., E.M. Aliouat, and M.L. Taylor,Surfactant proteins, SP-A and SP-D, in respiratory fungal infections: their role in the inflammatory response. Respiratory Research, 2016. 17 (1): p. 66.
30. Matsumura, Y., et al., Characterization and classification of ATP-binding cassette transporter ABCA3 mutants in fatal surfactant deficiency. Journal of Biological Chemistry, 2006. 281 (45): p. 34503-34514.
31. Weaver, T.E., Synthesis, processing and secretion of surfactant proteins B and C. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1998. 1408 (2): p. 173-179.
32. deFelice, M., et al., TTF-1 phosphorylation is required for peripheral lung morphogenesis, perinatal survival, and tissue-specific gene expression. Journal of Biological Chemistry, 2003.278 (37): p. 35574-35583.
33. Attarian, S.J., et al., Mutations in the thyroid transcription factor gene NKX2-1 result in decreased expression of SFTPB and SFTPC.Pediatric Research, 2018. 84 (3): p. 419-425.
34. Gupta, A. and S.L. Zheng, Genetic disorders of surfactant protein dysfunction: when to consider and how to investigate. Archives of disease in childhood, 2017. 102 (1): p. 84-90.
35. Nogee, L.M., Alterations in SP-B and SP-C expression in neonatal lung disease. Annu. Rev. Physiol., 2004. 66 : p. 601-623.
36. Nogee, L.M., Abnormal Expression of Surfactant Protein C and Lung Disease. American Journal of Respiratory Cell and Molecular Biology, 2002. 26 (6): p. 641-644.
37. Galetskiy, D., et al., Aberrant Processing Forms of Lung Surfactant Proteins SP–B and SP–C Revealed by High-Resolution Mass Spectrometry. European Journal of Mass Spectrometry, 2008.14 (6): p. 379-390.
38. Garmany, T.H., et al., Population and disease-based prevalence of the common mutations associated with surfactant deficiency.Pediatric research, 2008. 63 (6): p. 645-649.
39. Silveyra, P. and J. Floros, Genetic variant associations of human SP-A and SP-D with acute and chronic lung injury. Frontiers in bioscience (Landmark edition), 2012. 17 : p. 407-429.
40. Tredano, M., et al., Compound SFTPB 1549C→GAA (121ins2) and 457delC heterozygosity in severe congenital lung disease and surfactant protein B (SP-B) deficiency. Human Mutation, 1999. 14 (6): p. 502-509.
41. Nogee, L.M., et al., A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med, 2001. 344 (8): p. 573-9.
42. Mulugeta, S., et al., A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation. American journal of respiratory cell and molecular biology, 2005. 32 (6): p. 521-530.
43. Sánchez-Pulido, L., D. Devos, and A. Valencia, BRICHOS: a conserved domain in proteins associated with dementia, respiratory distress and cancer. Trends in Biochemical Sciences, 2002.27 (7): p. 329-332.
44. Wang, W.-J., et al., Deletion of exon 4 from human surfactant protein C results in aggresome formation and generation of a dominant negative. Journal of Cell Science, 2003. 116 (4): p. 683-692.
45. Hawkins, A., et al., A non-BRICHOS SFTPC mutant (SP-CI73T) linked to interstitial lung disease promotes a late block in macroautophagy disrupting cellular proteostasis and mitophagy. American Journal of Physiology-Lung Cellular and Molecular Physiology, 2015.308 (1): p. L33-L47.
46. Beers, M.F. and S. Mulugeta, Surfactant protein C biosynthesis and its emerging role in conformational lung disease. Annu Rev Physiol, 2005. 67 : p. 663-96.
47. Maguire, J.A., S. Mulugeta, and M.F. Beers, Endoplasmic Reticulum Stress Induced by Surfactant Protein C BRICHOS Mutants Promotes Proinflammatory Signaling by Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2011. 44 (3): p. 404-414.
48. Li, J., et al., The N-terminal Propeptide of Lung Surfactant Protein C is Necessary for Biosynthesis and Prevents Unfolding of a Metastable α-Helix. Journal of Molecular Biology, 2004.338 (5): p. 857-862.
49. Bullard, J.E., et al., ABCA3 mutations associated with pediatric interstitial lung disease. American journal of respiratory and critical care medicine, 2005. 172 (8): p. 1026-1031.
50. Brasch, F., et al., Alteration of the pulmonary surfactant system in full-term infants with hereditary ABCA3 deficiency. American journal of respiratory and critical care medicine, 2006.174 (5): p. 571-580.
51. Kröner, C., et al., Lung disease caused by <em>ABCA3</em> mutations.Thorax, 2017. 72 (3): p. 213-220.
52. Wambach, J.A., et al., Genotype-phenotype correlations for infants and children with ABCA3 deficiency. Am J Respir Crit Care Med, 2014. 189 (12): p. 1538-43.
53. Galambos, C., et al., Pulmonary pathology in thyroid transcription factor-1 deficiency syndrome. American journal of respiratory and critical care medicine, 2010. 182 (4): p. 549-554.
54. Carré, A., et al., Five new TTF1/NKX2.1 mutations in brain–lung–thyroid syndrome: rescue by PAX8 synergism in one case.Human Molecular Genetics, 2009. 18 (12): p. 2266-2276.
55. Moorsel, C.H.M.v., et al., Surfactant Protein C Mutations Are the Basis of a Significant Portion of Adult Familial Pulmonary Fibrosis in a Dutch Cohort. American Journal of Respiratory and Critical Care Medicine, 2010. 182 (11): p. 1419-1425.
56. Salerno, T., et al., Surfactant Protein C-associated interstitial lung disease; three different phenotypes of the same SFTPC mutation. Italian Journal of Pediatrics, 2016. 42 (1): p. 23.
57. Thouvenin, G., et al., Characteristics of disorders associated with genetic mutations of surfactant protein C. Archives of disease in childhood, 2010. 95 (6): p. 449-454.
58. Glasser, S.W., et al., Surfactant protein C-deficient mice are susceptible to respiratory syncytial virus infection. American Journal of Physiology-Lung Cellular and Molecular Physiology, 2009.297 (1): p. L64-L72.
59. Bridges, J.P., et al., Adaptation and increased susceptibility to infection associated with constitutive expression of misfolded SP-C.The Journal of cell biology, 2006. 172 (3): p. 395-407.
60. Abou Taam, R., et al., Familial interstitial disease with I73T mutation: A mid‐and long‐term study. Pediatric pulmonology, 2009.44 (2): p. 167-175.
61. Doan, M., et al., Clinical, radiological and pathological features of ABCA3 mutations in children. Thorax, 2008. 63 (4): p. 366-373.
62. Bullard, J.E. and L.M. Nogee, Heterozygosity for ABCA3 mutations modifies the severity of lung disease associated with a surfactant protein C gene (SFTPC) mutation. Pediatric Research, 2007.62 (2): p. 176-179.
63. Kleinlein, B., et al., Fatal neonatal respiratory failure in an infant with congenital hypothyroidism due to haploinsufficiency of the NKX2-1 gene: alteration of pulmonary surfactant homeostasis.Archives of Disease in Childhood-Fetal and Neonatal Edition, 2011.96 (6): p. F453-F456.
64. Nevel, R.J., et al., Persistent Lung Disease in Adults with NKX2.1 Mutation and Familial Neuroendocrine Cell Hyperplasia of Infancy. Annals of the American Thoracic Society, 2016. 13 (8): p. 1299-1304.
65. Deterding, R., Evaluating infants and children with interstitial lung disease. Semin Respir Crit Care Med, 2007.28 (3): p. 333-41.
66. Guillerman, R.P., Imaging of Childhood Interstitial Lung Disease. Pediatric allergy, immunology, and pulmonology, 2010.23 (1): p. 43-68.
67. Griese, M., et al., Expression profiles of hydrophobic surfactant proteins in children with diffuse chronic lung disease.Respiratory research, 2005. 6 (1): p. 80.
68. Al-Salmi, Q.A., et al., Serum KL-6 and surfactant proteins A and D in pediatric interstitial lung disease. Chest, 2005.127 (1): p. 403-407.
69. Langston, C., et al., A protocol for the handling of tissue obtained by operative lung biopsy: recommendations of the chILD pathology co-operative group. Pediatric and Developmental Pathology, 2006. 9 (3): p. 173-180.
70. Barbato, A., et al., A Delphi Consensus Of Clinician Approaches To Treatment In Children With Interstitial Lung Disease (ChILD) , in C50. CYSTIC FIBROSIS AND UNCOMMON PEDIATRIC DISEASES . p. A4664-A4664.
71. Kurland, G., et al., An official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy. American journal of respiratory and critical care medicine, 2013. 188 (3): p. 376-394.
72. Wert, S.E., J.A. Whitsett, and L.M. Nogee, Genetic disorders of surfactant dysfunction. Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society, 2009. 12 (4): p. 253-274.
73. Bruder, E., et al., Ultrastructural and molecular analysis in fatal neonatal interstitial pneumonia caused by a novel ABCA3 mutation.Modern Pathology, 2007. 20 (10): p. 1009-1018.
74. Wegner, D.J., et al., A major deletion in the surfactant protein-B gene causing lethal respiratory distress. Acta Paediatrica, 2007. 96 (4): p. 516-520.
75. Turcu, S., et al., Genetic testing in children with surfactant dysfunction. Archives of disease in childhood, 2013. 98 (7): p. 490-495.
76. Gower, W.A., et al., Fatal familial lung disease caused by ABCA3 deficiency without identified ABCA3 mutations. The Journal of pediatrics, 2010. 157 (1): p. 62-68.
77. Henderson, L.B., et al., Large ABCA3 and SFTPC deletions resulting in lung disease. Annals of the American Thoracic Society, 2013. 10 (6): p. 602-607.
78. Doan, M.L., et al., Serum KL-6 differentiates neuroendocrine cell hyperplasia of infancy from the inborn errors of surfactant metabolism. Thorax, 2009. 64 (8): p. 677-681.
79. Bush, A., et al., European protocols for the diagnosis and initial treatment of interstitial lung disease in children. Thorax, 2015. 70 (11): p. 1078-84.
80. Rama, J.A., et al., Lung transplantation for childhood diffuse lung disease. Pediatric Pulmonology, 2013. 48 (5): p. 490-496.
81. Williamson, M. and C. Wallis, Ten‐year follow up of hydroxychloroquine treatment for ABCA3 deficiency. Pediatric Pulmonology, 2014. 49 (3): p. 299-301.
82. Witt, S., et al., Medication for childhood interstitial lung diseases differs internationally. European Respiratory Journal, 2018.52 (suppl 62): p. PA634.
83. Breuer, O. and A. Schultz, Side effects of medications used to treat childhood interstitial lung disease. Paediatr Respir Rev, 2018.28 : p. 68-79.
84. Marmor, M.F., et al., Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).Ophthalmology, 2016. 123 (6): p. 1386-94.
85. Griese, M., et al., Prospective evaluation of hydroxychloroquine in pediatric interstitial lung diseases: Study protocol for an investigator-initiated, randomized controlled, parallel-group clinical trial. Trials, 2020. 21 (1): p. 307.
86. Cunningham, S., A. Jaffe, and L.R. Young, Children’s interstitial and diffuse lung disease. The Lancet Child & Adolescent Health, 2019. 3 (8): p. 568-577.
87. Walther, F.J., L.M. Gordon, and A.J. Waring, Advances in synthetic lung surfactant protein technology. Expert Review of Respiratory Medicine, 2019. 13 (6): p. 499-501.
88. Walther, F.J., L.M. Gordon, and A.J. Waring, Design of Surfactant Protein B Peptide Mimics Based on the Saposin Fold for Synthetic Lung Surfactants. Biomedicine hub, 2016. 1 (3): p. 1-21.
89. Lai, N.M., S.V. Rajadurai, and K. Tan, Increased energy intake for preterm infants with (or developing) bronchopulmonary dysplasia/chronic lung disease. Cochrane Database of Systematic Reviews, 2006(3).
90. Gilbert, C., A. Bush, and S. Cunningham, Childhood interstitial lung disease: Family experiences. Pediatr Pulmonol, 2015.50 (12): p. 1301-3.
91. Eldridge, W.B., et al., Outcomes of lung transplantation for infants and children with genetic disorders of surfactant metabolism.The Journal of pediatrics, 2017. 184 : p. 157-164. e2.
92. Elizur, A., et al., Lung transplantation in infants and toddlers from 1990 to 2004 at St. Louis Children’s Hospital. American Journal of Transplantation, 2009. 9 (4): p. 719-726.
93. Palomar, L.M., et al., Long-term outcomes after infant lung transplantation for surfactant protein B deficiency related to other causes of respiratory failure. The Journal of pediatrics, 2006.149 (4): p. 548-553.
94. Faro, A. and A. Hamvas, Lung transplantation for inherited disorders of surfactant metabolism. NeoReviews, 2008. 9 (10): p. e468-e476.
95. Fan, L.L., et al., Diffuse lung disease in biopsied children 2 to 18 years of age. Application of the chILD classification scheme.Annals of the American Thoracic Society, 2015. 12 (10): p. 1498-1505.
96. Stark, Z., et al., Australian Genomics: A Federated Model for Integrating Genomics into Healthcare. The American Journal of Human Genetics, 2019. 105 (1): p. 7-14.
97. Nathan, N., et al., A national internet-linked based database for pediatric interstitial lung diseases: the French network. Orphanet journal of rare diseases, 2012. 7 (1): p. 40.